Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma (NCT05180097)
A Randomized Phase II Study of Pembrolizumab and Brentuximab Vedotin Versus GDP, Followed by High Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed/Refractory Classical Hodgkin Lymphoma
🩺 Plain-English Summary (8th-Grade Level)
This study is being done to determine if two new drugs can shrink or eliminate classical Hodgkins lymphoma.
Who can join: Review the eligibility criteria below.
Location: Concord Repatriation General Hospital — Concord, New South Wales
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (18 Sites)
- Concord Repatriation General Hospital — Concord, New South Wales
- Shoalhaven Cancer Care Centre — Nowra, New South Wales
- Wollongong Hospital — Wollongong, New South Wales
- Royal Adelaide Hospital — Adelaide, South Australia
- Austin Hospital — Heidelberg, Victoria
- Sir Charles Gairdner Hospital — Perth, Western Australia
- Arthur J.E. Child Comprehensive Cancer Centre — Calgary, Alberta
- BCCA - Vancouver — Vancouver, British Columbia
- Dr. H. Bliss Murphy Cancer Centre — St. John's, Newfoundland and Labrador
- QEII Health Sciences Centre — Halifax, Nova Scotia
- Juravinski Cancer Centre at Hamilton Health Sciences — Hamilton, Ontario
- London Health Sciences Centre Research Inc. — London, Ontario
- Ottawa Hospital Research Institute — Ottawa, Ontario
- University Health Network — Toronto, Ontario
- The Jewish General Hospital — Montreal, Quebec
- The Research Institute of the McGill University — Montreal, Quebec
- CIUSSS de l'Estrie - Centre hospitalier — Sherbrooke, Quebec
- Allan Blair Cancer Centre — Regina, Saskatchewan
📞 Contact the Study Coordinator
Phone: (613) 533-6430
Email: ahay@ctg.queensu.ca
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Hodgkin Lymphoma
- Evaluating Combination of Nivolumab and Axatilimab in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma — Detroit, Michigan
- Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667) — Birmingham, Alabama
- PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma — Houston, Texas
- Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor for Lymphoma — Salt Lake City, Utah
- A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL) — Detroit, Michigan
- Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHL — Chicago, Illinois
Explore by condition: All Hodgkin Lymphoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.